Furthermore, there is evidence indicating that blocking the sortilin-neurotensin or sortilin-progranulin interactions might be of interest for the treatment of neuropathic pain (64) and certain forms of breast cancer (65, 66), respectively. This evidence concerns the gene GRN and breast carcinoma.